Colorectal cancer (mCRC) is the fourth most common cancer among men and women. About 40 % of mCRC patients have mutations of the KRAS gene in the tumor. Tumors with KRAS mutations in codons 12 or 13 are resistant to anti-EGFR therapy. Accordingly, treatment with drugs for the anti-EGFR therapy of mCRC like Erbitux® or Vectibix® is recommended only for tumors without such mutations.
Indications for Testing
Targeted therapy of metastatic colorectal cancer (mCRC).
Sample Material
- Fresh tissue
- Fresh-frozen tissue
- Formalin fixed paraffin embedded (FFPE) tissue
Mutant codon – Nucleotides
- G12C – TGT
- G12S – AGT
- G12R – CGT
- G12V – GTT
- G12D – GAT
- G12A – GCT
- G13D – GAC
